I found information about the intra-arterial administration of bevacizumab. It looks very interesting.
Does anyone know any details?
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
2017 https://www.ncbi.nlm.nih.gov/pubmed/28472567
"Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year."
2012 https://www.ncbi.nlm.nih.gov/pubmed/22946342
Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model.
Mannitol was used to prepare the solution:
https://www.drugs.com/monograph/mannitol.html
The practice of such treatment in Ukraine:
2013 https://cyberleninka.ru/article/n/ispolzovanie-metoda-vnutriarterialnogo-vvedeniya-himiopreparatov-v-sostave-kompleksnogo-lecheniya-patsientov-s-gliomami-golovnogo
For the intra-arterial administration of drugs, the endovascular technique was used.
"It was found that the method of intra-arterial delivery of chemotherapy is effective and efficient in treatment of patients with malignant gliomas of the brain, can reduce the toxic effects of chemotherapy on the patient, to improve the quality of life for patients."
Does anyone know any details?
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
2017 https://www.ncbi.nlm.nih.gov/pubmed/28472567
"Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year."
2012 https://www.ncbi.nlm.nih.gov/pubmed/22946342
Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model.
Mannitol was used to prepare the solution:
https://www.drugs.com/monograph/mannitol.html
The practice of such treatment in Ukraine:
2013 https://cyberleninka.ru/article/n/ispolzovanie-metoda-vnutriarterialnogo-vvedeniya-himiopreparatov-v-sostave-kompleksnogo-lecheniya-patsientov-s-gliomami-golovnogo
For the intra-arterial administration of drugs, the endovascular technique was used.
"It was found that the method of intra-arterial delivery of chemotherapy is effective and efficient in treatment of patients with malignant gliomas of the brain, can reduce the toxic effects of chemotherapy on the patient, to improve the quality of life for patients."
No comments:
Post a Comment